Biology subjects

Satas, G.

Publications and source records attributed to Satas, G..

9 recordsLinked to original sources

bioRxiv2026

Statistical Inconsistency of Error-correction Objectives for Perfect Phylogenies

The binary perfect phylogeny, in which each mutation arises exactly once on an evolutionary tree and is never lost, is a well-studied idealized phylogenetic model. When observed data has errors, a common approach to phylogeny inference is to seek a tree that minimizes the number of error corrections ("flips") needed to fit a perfect phylogeny. These objectives draw on an intuitive justification: minimizing implied errors should prefer the true tree in expectation. We test this assumption using a generative model with independent errors and prove that error-correction objectives are statistically inconsistent for all positive error rates: in expectation, the minimum-cost tree need not be the true tree. Our proof is constructive and yields counterexamples involving any tree topology and any positive error rates, demonstrating the ubiquity of the phenomenon. The core problem is that tree topologies can explain observed mutation patterns with fewer errors than actually occurred, and differ in their ability to do so, introducing systematic bias. This mechanism is distinct from previously identified sources of inconsistency such as homoplasy or incomplete lineage sorting, since the error-free setting is trivially consistent for perfect phylogenies. We investigate how often this failure may occur in practice. Simulations calibrated to error rates from single-cell sequencing data show that an incorrect tree is preferred over the true tree in a substantial fraction of cases (over 50% in some settings) with rates increasing with tree size. Moreover, winning trees are not random but share specific topological features. Notably, at error rates typical of single-cell sequencing data, trees with deeper, more imbalanced topologies are consistently favored over more balanced ones. These results demonstrate that inconsistency is not a theoretical edge case, and that understanding when and how it arises is important when interpreting results in practice. Supplementary MaterialSource code: https://github.com/shahcompbio/phylo_inconsistency FundingThis research was supported in part by NCI SPORE (P50 CA247749-01)

bioinformatics↗

bioRxiv2026

scPlOver: inferring DNA content from amplification-free single-cell WGS using fragment overlaps

Correctly inferring copy-number aberrations from single-cell DNA sequencing data requires estimating cellular DNA content, which is unidentifiable from read counts alone. In tagmentation-based sequencing, each fragment represents a distinct DNA molecule, thus fragment overlaps provide an orthogonal signal for copy number. We present a theoretical model of fragment overlaps as a function of copy number and coverage and introduce scPlOver, a method that uses this model to infer DNA content. scPlOver outperforms existing approaches on simulated and experimental datasets and identifies thousands of ovarian cancer cells with higher DNA content than previously estimated across a cohort of 41 patients.

genomics↗

bioRxiv2025

Inferring active mutational processes in cancer using single cell sequencing and evolutionary constraints

Ongoing mutagenesis in cancer drives genetic diversity throughout the natural history of cancers. As the activities of mutational processes are dynamic throughout evolution, distinguishing the mutational signatures of active and historical processes has important implications for studying how tumors evolve. This can aid in understanding mutagenic states at the time of presentation, and in associating active mutational process with therapeutic resistance. As bulk sequencing primarily captures historical mutational processes, we studied whether ultra-low-coverage single-cell whole-genome sequencing (scWGS), which measures the distribution of mutations across hundreds or thousands of individual cells, could enable the distinction between historical and active mutational processes. While technical challenges and data sparsity have limited mutation analysis in scWGS, we show that these data contain valuable information about dynamic mutational processes. To robustly interpret single nucleotide variants (SNVs) in scWGS, we introduce ArtiCull, a method to identify and remove SNV artifacts by leveraging evolutionary constraints, enabling reliable detection of mutations for signature analysis. Applying this approach to scWGS data from pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), and high-grade serous ovarian cancer (HGSOC), we uncover temporal and spatial patterns in mutational processes. In PDAC, we observe a temporal increase in mismatch repair deficiency (MMRd). In cisplatin-treated TNBC patient-derived xenografts, we identify therapy-induced mutagenesis and inactivation of APOBEC3 activity. In HGSOC, we show distinct patterns of APOBEC3 mutagenesis, including late tumor-wide activation in one case and clade-specific enrichment in another. Additionally, we detect a clone-specific increase in SBS17 activity, in a clone previously linked to recurrence. Our findings establish ultra-low-coverage scWGS as a powerful approach for studying active mutational processes that may influence ongoing clonal evolution and therapeutic resistance.

cancer biology↗

bioRxiv2024

Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA

Drug resistance is the major cause of therapeutic failure in high-grade serous ovarian cancer (HGSOC). Yet, the mechanisms by which tumors evolve to drug resistant states remains largely unknown. To address this, we aimed to exploit clone-specific genomic structural variations by combining scaled single-cell whole genome sequencing with longitudinally collected cell-free DNA (cfDNA), enabling clonal tracking before, during and after treatment. We developed a cfDNA hybrid capture, deep sequencing approach based on leveraging clone-specific structural variants as endogenous barcodes, with orders of magnitude lower error rates than single nucleotide variants in ctDNA (circulating tumor DNA) detection, demonstrated on 19 patients at baseline. We then applied this to monitor and model clonal evolution over several years in ten HGSOC patients treated with systemic therapy from diagnosis through recurrence. We found drug resistance to be polyclonal in most cases, but frequently dominated by a single high-fitness and expanding clone, reducing clonal diversity in the relapsed disease state in most patients. Drug-resistant clones frequently displayed notable genomic features, including high-level amplifications of oncogenes such as CCNE1, RAB25, NOTCH3, and ERBB2. Using a population genetics Wright-Fisher model, we found evolutionary trajectories of these features were consistent with drug-induced positive selection. In select cases, these alterations impacted selection of secondary lines of therapy with positive patient outcomes. For cases with matched single-cell RNA sequencing data, pre-existing and genomically encoded phenotypic states such as upregulation of EMT and VEGF were linked to drug resistance. Together, our findings indicate that drug resistant states in HGSOC pre-exist at diagnosis and lead to dramatic clonal expansions that alter clonal composition at the time of relapse. We suggest that combining tumor single cell sequencing with cfDNA enables clonal tracking in patients and harbors potential for evolution-informed adaptive treatment decisions.

cancer biology↗

bioRxiv2024

Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer

Whole-genome doubling (WGD) is a critical driver of tumor development and is linked to drug resistance and metastasis in solid malignancies. Here, we demonstrate that WGD is an ongoing mutational process in tumor evolution. Using single-cell whole-genome sequencing, we measured and modeled how WGD events are distributed across cellular populations within tumors and associated WGD dynamics with properties of genome diversification and phenotypic consequences of innate immunity. We studied WGD evolution in 65 high-grade serous ovarian cancer (HGSOC) tissue samples from 40 patients, yielding 29,481 tumor cell genomes. We found near-ubiquitous evidence of WGD as an ongoing mutational process promoting cell-cell diversity, high rates of chromosomal missegregation, and consequent micronucleation. Using a novel mutation-based WGD timing method, doubleTime, we delineated specific modes by which WGD can drive tumor evolution: (i) unitary evolutionary origin followed by significant diversification, (ii) independent WGD events on a pre-existing background of copy number diversity, and (iii) evolutionarily late clonal expansions of WGD populations. Additionally, through integrated single-cell RNA sequencing and high-resolution immunofluorescence microscopy, we found that inflammatory signaling and cGAS-STING pathway activation result from ongoing chromosomal instability and are restricted to tumors that remain predominantly diploid. This contrasted with predominantly WGD tumors, which exhibited significant quiescent and immunosuppressive phenotypic states. Together, these findings establish WGD as an evolutionarily active mutational process that promotes evolvability and dysregulated immunity in late stage ovarian cancer.

cancer biology↗

bioRxiv2023

Exploiting allele-specific transcriptional effects of subclonal copy number alterations for genotype-phenotype mapping in cancer cell populations

Somatic copy number alterations drive aberrant gene expression in cancer cells. In tumors with high levels of chromosomal instability, subclonal copy number alterations (CNAs) are a prevalent feature which often result in heterogeneous cancer cell populations with distinct phenotypes1. However, the extent to which subclonal CNAs contribute to clone-specific phenotypes remains poorly understood, in part due to the lack of methods to quantify how CNAs influence gene expression at a subclone level. We developed TreeAlign, which computationally integrates independently sampled single-cell DNA and RNA sequencing data from the same cell population and explicitly models gene dosage effects from subclonal alterations. We show through quantitative benchmarking data and application to human cancer data with single cell DNA and RNA libraries that TreeAlign accurately encodes clone-specific transcriptional effects of subclonal CNAs, the impact of allelic imbalance on allele-specific transcription, and obviates the need to arbitrarily define genotypic clones from a phylogenetic tree a priori. Combined, these advances lead to highly granular definitions of clones with distinct copy-number driven expression programs with increased resolution and accuracy over competing methods. The resulting improvement in assignment of transcriptional phenotypes to genomic clones enables clone-clone gene expression comparisons and explicit inference of genes that are mechanistically altered through CNAs, and identification of expression programs that are genomically independent. Our approach sets the stage for dissecting the relative contribution of fixed genomic alterations and dynamic epigenetic processes on gene expression programs in cancer.

cancer biology↗

bioRxiv2021

DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolution

Most tumors are heterogeneous mixtures of normal cells and cancer cells, with individual cancer cells distinguished by somatic mutations that accumulated during the evolution of the tumor. The fundamental quantity used to measure tumor heterogeneity from somatic single-nucleotide variants (SNVs) is the Cancer Cell Fraction (CCF), or proportion of cancer cells that contain the SNV. However, in tumors containing copy-number aberrations (CNAs) - e.g. most solid tumors - the estimation of CCFs from DNA sequencing data is challenging because a CNA may alter the mutation multiplicity, or number of copies of an SNV. Existing methods to estimate CCFs rely on the restrictive Constant Mutation Multiplicity (CMM) assumption that the mutation multiplicity is constant across all tumor cells containing the mutation. However, the CMM assumption is commonly violated in tumors containing CNAs, and thus CCFs computed under the CMM assumption may yield unrealistic conclusions about tumor heterogeneity and evolution. The CCF also has a second limitation for phylogenetic analysis: the CCF measures the presence of a mutation at the present time, but SNVs may be lost during the evolution of a tumor due to deletions of chromosomal segments. Thus, SNVs that co-occur on the same phylogenetic branch may have different CCFs. In this work, we address these limitations of the CCF in two ways. First, we show how to compute the CCF of an SNV under a less restrictive and more realistic assumption called the Single Split Copy Number (SSCN) assumption. Second, we introduce a novel statistic, the descendant cell fraction (DCF), that quantifies both the prevalence of an SNV and the past evolutionary history of SNVs under an evolutionary model that allows for mutation losses. That is, SNVs that co-occur on the same phylogenetic branch will have the same DCF. We implement these ideas in an algorithm named DeCiFer. DeCiFer computes the DCFs of SNVs from read counts and copy-number proportions and also infers clusters of mutations that are suitable for phylogenetic analysis. We show that DeCiFer clusters SNVs more accurately than existing methods on simulated data containing mutation losses. We apply DeCiFer to sequencing data from 49 metastatic prostate cancer samples and show that DeCiFer produces more parsimonious and reasonable reconstructions of tumor evolution compared to previous approaches. Thus, DeCiFer enables more accurate quantification of intra-tumor heterogeneity and improves downstream inference of tumor evolution. Code availabilitySoftware is available at https://github.com/raphael-group/decifer

bioinformatics↗

bioRxiv2019

Single-cell tumor phylogeny inference with copy-number constrained mutation losses

MotivationSingle-cell DNA sequencing enables the measurement of somatic mutations in individual tumor cells, and provides data to reconstruct the evolutionary history of the tumor. Nearly all existing methods to construct phylogenetic trees from single-cell sequencing data use single-nucleotide variants (SNVs) as markers. However, most solid tumors contain copy-number aberrations (CNAs) which can overlap loci containing SNVs. Particularly problematic are CNAs that delete an SNV, thus returning the SNV locus to the unmutated state. Such mutation losses are allowed in some models of SNV evolution, but these models are generally too permissive, allowing mutation losses without evidence of a CNA overlapping the locus. ResultsWe introduce a novel loss-supported evolutionary model, a generalization of the infinite sites and Dollo models, that constrains mutation losses to loci with evidence of a decrease in copy number. We design a new algorithm, Single-Cell Algorithm for Reconstructing the Loss-supported Evolution of Tumors (SO_SCPLOWCARLETC_SCPLOW), that infers phylogenies from single-cell tumor sequencing data using the loss-supported model and a probabilistic model of sequencing errors and allele dropout. On simulated data, we show that SO_SCPLOWCARLETC_SCPLOW outperforms current single-cell phylogeny methods, recovering more accurate trees and correcting errors in SNV data. On single-cell sequencing data from a metastatic colorectal cancer patient, SO_SCPLOWCARLETC_SCPLOW constructs a phylogeny that is both more consistent with the observed copy-number data and also reveals a simpler monooclonal seeding of the metastasis, contrasting with published reports of polyclonal seeding in this patient. SO_SCPLOWCARLETC_SCPLOW substantially improves single-cell phylogeny inference in tumors with CNAs, yielding new insights into the analysis of tumor evolution. AvailabilitySoftware is available at github.com/raphael-group/scarlet Contactbraphael@princeton.edu

genomics↗

bioRxiv2019

Inferring tumor evolution from longitudinal samples

Background: Determining the clonal composition and somatic evolution of a tumor greatly aids in accurate prognosis and effective treatment for cancer. In order to understand how a tumor evolves over time and/or in response to treatment, multiple recent studies have performed longitudinal DNA sequencing of tumor samples from the same patient at several different time points. However, none of the existing algorithms that infer clonal composition and phylogeny using several bulk tumor samples from the same patient integrate the information that these samples were obtained from longitudinal observations. Results: We introduce a model for a longitudinally-observed phylogeny and derive constraints that longitudinal samples impose on the reconstruction of a phylogeny from bulk samples. These constraints form the basis for a new algorithm, Cancer Analysis of Longitudinal Data through Evolutionary Reconstruction (CALDER), which infers phylogenetic trees from longitudinal bulk DNA sequencing data. We show on simulated data that constraints from longitudinal sampling can substantially reduce ambiguity when deriving a phylogeny from multiple bulk tumor samples, each a mixture of tumor clones. On real data, where there is often considerable uncertainty in the clonal composition of a sample, longitudinal constraints yield more parsimonious phylogenies with fewer tumor clones per sample. We demonstrate that CALDER reconstructs more plausible phylogenies than existing methods on two longitudinal DNA sequencing datasets from chronic lymphocytic leukemia patients. These findings show the advantages of directly incorporating temporal information from longitudinal sampling into tumor evolution studies. Availability: CALDER is available at https://github.com/raphael-group.

bioinformatics↗